IONS

Business Context and Reporting Period

Company: Isis Pharmaceuticals, Inc. (now Ionis Pharmaceuticals)

Reporting Period: Fiscal year ended December 31, 2006

Overview: Isis is a biopharmaceutical company specializing in RNA-based drug discovery, primarily using antisense technology to inhibit disease-causing proteins. The company operates two main segments: Drug Discovery and Development (focusing on cardiovascular and metabolic diseases) and Ibis Biosciences (a subsidiary developing the Ibis T5000 Biosensor System for infectious disease identification). The company has no marketed products generating significant commercial revenue; its primary approved drug, Vitravene, is no longer marketed by its partner.

Key Financial Metrics

Note: The 2006 net loss includes a $23.0 million benefit attributed to the noncontrolling interest in Symphony GenIsis, Inc., a variable interest entity consolidated in 2006.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 39% to $24.5 million, primarily due to a reduction in revenue from the Eli Lilly collaboration (which was extended to focus on fewer targets) and lower government contract revenue for Ibis Biosciences.
• Improved Net Loss: Net loss applicable to common stock improved significantly (36% reduction) to $45.9 million. This improvement was driven by the $23.0 million noncontrolling interest benefit from Symphony GenIsis, a decrease in interest expense (due to the conversion of the Lilly loan to equity), and a gain on investments, partially offset by a higher operating loss.
• Liquidity Strengthening: Cash and short-term investments more than doubled to $193.3 million. This was fueled by a $75 million equity financing from Azimuth Opportunity Ltd., the consolidation of Symphony GenIsis cash, and proceeds from stock option exercises.
• Debt Restructuring: In January 2007 (post-period), the company issued $162.5 million in new convertible notes to repurchase higher-interest existing notes, reducing annual interest payments by approximately $2.6 million.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Drug Pipeline: The company reported positive Phase 2 results for ISIS 301012 (cholesterol) and ISIS 113715 (diabetes). ISIS 301012 showed potent, dose-dependent reductions in LDL and triglycerides. ISIS 113715 reduced glucose levels but did not show statistically significant improvement in HbA1c in a short-term study.
• Financing Strategy: The company secured $75 million from Symphony GenIsis to fund the development of ISIS 301012 and two metabolic drugs. Management believes current resources are sufficient to meet requirements through at least mid-2010.
• Ibis Commercialization: Ibis Biosciences began commercializing the T5000 Biosensor System, securing its first commercial orders and a contract for assay services. Manufacturing and support have been transitioned to partner Bruker Daltonics.

Risks and Contingencies

• Profitability: The company has incurred losses since inception (accumulated deficit of $816.8 million) and expects to incur additional losses. Future profitability depends on successful drug development and commercialization.
• Regulatory Approval: All drugs are in development; failure to obtain FDA approval for lead candidates (ISIS 301012, ISIS 113715) would prevent revenue generation from product sales.
• Government Contract Dependency: Ibis Biosciences relies heavily on U.S. government contracts (37% of total revenue in 2006). These contracts can be terminated at the government's convenience.
• Intellectual Property: Success depends on maintaining patent protection. The company faces potential litigation risks regarding its patent portfolio.

Key Facts for Investor Verification

• Revenue Concentration: Verify the sustainability of revenue streams, as the company relies heavily on milestone payments and government grants rather than product sales.
• Symphony GenIsis Accounting: Confirm the impact of the $23.0 million noncontrolling interest benefit on the reported net loss and the terms of the purchase option to reacquire the assets.
• Cash Burn Rate: Assess the runway of the $193.3 million cash balance against the $80.6 million annual R&D spend and operating expenses.
• Clinical Trial Results: Monitor upcoming Phase 2 and Phase 3 data for ISIS 301012 and ISIS 113715, as these are critical value inflection points.
• Debt Obligations: Review the terms of the $125 million 5.5% convertible notes due 2009 and the new $162.5 million 2.625% notes issued in early 2007.